898 abstracts found.



Results filter

Promoting Patient Safety in Clinical Trials: A Survey of Progress in Out-of-Hours Systems in the Experimental Cancer Medicine Centre (ECMC) Network

Year:

Session type:

Ruth Boyd1, Libby Batt2, Pam Baxter3, Debbie Beirne4, Dorothy Boyle5, Hannah Brown6, Sophia Campbell7, Fiona Chapman8, Tracy Clark9, Alison Clarke10, Karen Doyle11, Todd Gumbleton12, Lynn Hope13, Linda Jones14, Lydianne Lock15, Teresa Lockett16, Jac Samuel17, Sandie Wellman18, Sharon Whelan19, Laura Woodley20,
1Northern Ireland Cancer Trials Centre, Belfast City Hospital, Belfast, UK,2Clinical Research Treatment Unit, Velindre Cancer Centre, Cardiff, UK,3Plymouth University Peninsula Schools of Medicine & Dentistry, Plymouth, UK,4Cancer Research UK Leeds Cancer Centre/Experimental Cancer Medicine Centre, Leeds, UK,5Scottish Cancer Research Network South East, Western General Hospital, Edinburgh, UK,6Experimental Cancer Medicine Centre Network Secretariat, London, UK,7Beatson West of Scotland Cancer Centre, Glasgow, UK,8Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK,9Oak Ward Drug Development Unit, Royal Marsden Hospital, Sutton, UK,10Cancer Research Centre, Weston Park Hospital, Sheffield, UK,11Cancer Research UK Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham, UK,12Clinical Research Facility, University College London Hospital, London, UK,13The Christie NHS Foundation Trust, Manchester, UK,14University of Cambridge, Cambridge, UK,15Leicester Royal Infirmary, Leicester, UK,16Addenbrooke's Hospital, Cambridge, UK,17Southampton Experimental Cancer Centre, Southampton, UK

A novel cell surface pancreatic and cholangiocarcinoma biomarker that promotes resistance to Gemcitabine

Year:

Session type:

Jonathan Kay1, Laura Bucklow1, Rebecca Brais2, Hayley Luxton1, Aarthi Gopinathan3, Duncan Jodrell3, Hayley Whitaker1,
1Cancer Research UK Cambridge Biomarker Initiative, Cambridge, UK,2Department of Pathology, Addenbrookes Hospital, Cambridge, UK,3Pharmacology and Drug Development Group, Cancer Research UK Cambridge Institute, Cambridge, UK

The National Cancer Research Institute Clinical Studies Group portfolio triaging analysis: A tool to monitor funding and recruitment activity within the NCRI CSG portfolio

Year:

Session type:

Michelle Cashin-Cox1, Seema Alexander1, Eileen Loucaides1, Rachel Moser2, Matt Seymour2,
1National Cancer Research Institute Clinical Studies Groups Secretariat, London, UK,NIHR CRN: CancerNational Institute for Health Research Clinical Research Network: Cancer

Unemployment, public-sector healthcare spending and stomach cancer mortality in the European Union, 1981-2009

Year:

Session type:

Annabelle Painter1, Johnathan Watkins2, Callum Williams2, Raghib Ali2, Thomas Zeltner2, Omar Faiz2, Hemant Sheth2, Mahiben Maruthappu2,
1University of Oxford, Oxford, UK,2NHS England, England, UK

Implementing the first phase of HRA Approval through the Experimental Cancer Medicine Centre (ECMC) Network: Streamlining pharmacy review

Year:

Session type:

Nicholas Wong1, Wendy Fisher2, Jonathan Fennelly-Barnwell3, Tristan Furnell4, Anna Zaniewska4, Aoife Regan1, Janet Messer3,
ECMCExperimental Cancer Medicine Centre,2Wendy Fisher Consulting Ltd, London, UK,HRAHealth Research Authority,DDODrug Development Office

Audit of rate of BRCA1/2 detection when all patients with papillary serous ovarian cancer are tested,regardless of family history or manchester score

Year:

Session type:

Elspeth Murray1, Michelle Ferguson2,
1University of Dundee, Dundee, UK,2NHS Tayside, Dundee, UK

Early Stage Endometrial Cancer treated with surgery and no adjuvant treatment – To Follow-up or Not?

Year:

Session type:

Moray Kyle1, Alison Stillie1,
1Edinburgh Cancer Centre, Edinburgh, UK

Sterilization and ovarian cancer in the Million Women Study: variation by histological subtype

Year:

Session type:

Kezia Gaitskell1, Jane Green1, Kirstin Pirie1, Gillian Reeves1, Valerie Beral1,
1Cancer Epidemiology Unit, University of Oxford, Oxford, UK

Regulation of cell cycle by the epigenetic modifiers KMT2C and KMT2D and their therapeutic potential in Pancreatic Ductal Adenocarcinoma (PDAC)

Year:

Session type:

Joshua Dawkins1, Eleni Maniati1, Thorsten Hagemann1,
1Barts Cancer Institute, London, UK

Insulin-like growth factor-I and risk of differentiated thyroid carcinoma in the European Prospective Investigation into Cancer and Nutrition

Year:

Session type:

Julie A Schmidt1, Ruth C Travis1,
1Cancer Epidemiology Unit, University of Oxford, Oxford, UK

Page 25 of 90« First...25...50...Last »